Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Jul 3;92(14):6537–6541. doi: 10.1073/pnas.92.14.6537

Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries.

X Cai 1, A Garen 1
PMCID: PMC41553  PMID: 7604028

Abstract

Fusion phage libraries expressing single-chain Fv antibodies were constructed from the peripheral blood lymphocytes of two melanoma patients who had been immunized with autologous melanoma cells transduced the gamma-interferon gene to enhance immunogenicity, in a trial conducted at another institution. Anti-melanoma antibodies were selected from each library by panning the phage against live cultures of the autologous tumor. After two or three rounds of panning, clones of the phage were tested by ELISA for binding to the autologous tumor cells; > 90% of the clones tested showed a strong ELISA reaction, demonstrating the effectiveness of the panning procedure for selecting antimelanoma antibodies. The panned phage population was extensively absorbed against normal melanocytes to enrich for antibodies that react with melanoma cells but not with melanocytes. The unabsorbed phage were cloned, and the specificities of the expressed antibodies were individually tested by ELISA with a panel of cultured human cells. The first tests were done with normal endothelial and fibroblast cells to identify antibodies that do not react, or react weakly, with two normal cell types, indicating some degree of specificity for melanoma cells. The proportion of phage clones expressing such antibodies was approximately 1%. Those phage were further tested by ELISA with melanocytes, several melanoma lines, and eight other tumor lines, including a glioma line derived from glial cells that share a common lineage with melanocytes. The ELISA tests identified three classes of anti-melanoma antibodies, as follows: (i) a melanoma-specific class that reacts almost exclusively with the melanoma lines; (ii) a tumor-specific class that reacts with melanoma and other tumor lines but does not react with the normal melanocyte, endothelial and fibroblast cells; and (iii) a lineage-specific class that reacts with the melanoma lines, melanocytes, and the glioma line but does not react with the other lines. These are rare classes from the immunized patients' repertoires of anti-melanoma antibodies, most of which are relatively nonspecific anti-self antibodies. The melanoma-specific class was isolated from one patient, and the lineage-specific class was isolated from the other patient, indicating that different patients can have markedly different responses to the same immunization protocol. The procedures described here can be used to screen the antibody repertoire of any person with cancer, providing access to an enormous untapped pool of human monoclonal anti-tumor antibodies with clinical and research potential.

Full text

PDF
6537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbas C. F., 3rd, Kang A. S., Lerner R. A., Benkovic S. J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7978–7982. doi: 10.1073/pnas.88.18.7978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chaudhuri T. R., Zinn K. R., Morris J. S., McDonald G. A., Llorens A. S., Chaudhuri T. K. Human monoclonal antibody developed against ovarian cancer cell surface antigen. Cancer. 1994 Feb 1;73(3 Suppl):1098–1104. doi: 10.1002/1097-0142(19940201)73:3+<1098::aid-cncr2820731350>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  3. Ditzel H., Rasmussen J. W., Erb K., Borup-Christensen P., Titlestad I., Lassen E., Fenger C., Kronborg O., Jensenius J. C. Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Res. 1993 Dec 15;53(24):5920–5928. [PubMed] [Google Scholar]
  4. Don R. H., Cox P. T., Wainwright B. J., Baker K., Mattick J. S. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res. 1991 Jul 25;19(14):4008–4008. doi: 10.1093/nar/19.14.4008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dranoff G., Mulligan R. C. Gene transfer as cancer therapy. Adv Immunol. 1995;58:417–454. doi: 10.1016/s0065-2776(08)60624-0. [DOI] [PubMed] [Google Scholar]
  6. Ghetie M. A., Vitetta E. S. Recent developments in immunotoxin therapy. Curr Opin Immunol. 1994 Oct;6(5):707–714. doi: 10.1016/0952-7915(94)90073-6. [DOI] [PubMed] [Google Scholar]
  7. Griffiths A. D., Malmqvist M., Marks J. D., Bye J. M., Embleton M. J., McCafferty J., Baier M., Holliger K. P., Gorick B. D., Hughes-Jones N. C. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb;12(2):725–734. doi: 10.1002/j.1460-2075.1993.tb05706.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hall B. L., Murray J. H., Haspel M. V., Kobrin B. J. Establishment, molecular rescue, and expression of 123AV16-1, a tumor-reactive human monoclonal antibody. Cancer Res. 1994 Oct 1;54(19):5178–5185. [PubMed] [Google Scholar]
  9. Haspel M. V., McCabe R. P., Pomato N., Janesch N. J., Knowlton J. V., Peters L. C., Hoover H. C., Jr, Hanna M. G., Jr Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res. 1985 Aug;45(8):3951–3961. [PubMed] [Google Scholar]
  10. Herlyn M., Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol. 1988;6:283–308. doi: 10.1146/annurev.iy.06.040188.001435. [DOI] [PubMed] [Google Scholar]
  11. Hoon D. S., Wang Y., Sze L., Kanda H., Watanabe T., Morrison S. L., Morton D. L., Irie R. F. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res. 1993 Nov 1;53(21):5244–5250. [PubMed] [Google Scholar]
  12. Koda K., Glassy M. C., Chang H. R. Generation of human monoclonal antibodies against colon cancer. Arch Surg. 1990 Dec;125(12):1591–1597. doi: 10.1001/archsurg.1990.01410240073015. [DOI] [PubMed] [Google Scholar]
  13. Lloyd K. O. Tumor antigens known to be immunogenic in man. Ann N Y Acad Sci. 1993 Aug 12;690:50–58. doi: 10.1111/j.1749-6632.1993.tb43995.x. [DOI] [PubMed] [Google Scholar]
  14. Marks J. D., Griffiths A. D., Malmqvist M., Clackson T. P., Bye J. M., Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y) 1992 Jul;10(7):779–783. doi: 10.1038/nbt0792-779. [DOI] [PubMed] [Google Scholar]
  15. Marks J. D., Hoogenboom H. R., Bonnert T. P., McCafferty J., Griffiths A. D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991 Dec 5;222(3):581–597. doi: 10.1016/0022-2836(91)90498-u. [DOI] [PubMed] [Google Scholar]
  16. Pai L. H., Pastan I. Immunotoxin therapy for cancer. JAMA. 1993 Jan 6;269(1):78–81. [PubMed] [Google Scholar]
  17. Parmley S. F., Smith G. P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene. 1988 Dec 20;73(2):305–318. doi: 10.1016/0378-1119(88)90495-7. [DOI] [PubMed] [Google Scholar]
  18. Scott J. K., Smith G. P. Searching for peptide ligands with an epitope library. Science. 1990 Jul 27;249(4967):386–390. doi: 10.1126/science.1696028. [DOI] [PubMed] [Google Scholar]
  19. Winter G., Milstein C. Man-made antibodies. Nature. 1991 Jan 24;349(6307):293–299. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES